Allrock Bio Raises $50M to advance pulmonary arterial hypertension (PAH) and pulmonary hypertension due to interstitial lung disease (PH-ILD) Treatment ROC-101 into Phase 2a Trials

Allrock Bio raised $50M to fund Phase 2a trials of ROC-101, an oral treatment for pulmonary hypertension. The ROCSTAR trial will test ROC-101 combined with standard therapies in pulmonary arterial hypertension (PAH) and pulmonary hypertension due to underlying interstitial lung disease (PH-ILD) patients, starting late 2025. ROC-101 blocks ROCK1 and ROCK2 proteins to reduce inflammation, scarring, and abnormal cell growth. Phase 1 data showed favorable safety and promising biological activity levels.

Read more at this link on Pulmonary Hypertension News